We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+3.23%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$472B
AUM Growth
+$3.53B
Cap. Flow
-$5.2B
Cap. Flow %
-1.1%
Top 10 Hldgs %
16.24%
Holding
2,596
New
95
Increased
1,094
Reduced
954
Closed
84

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.2B
2
AGN
Allergan plc
AGN
+$1.03B
3
GILD icon
Gilead Sciences
GILD
+$917M
4
PFE icon
Pfizer
PFE
+$901M
5
NKE icon
Nike
NKE
+$872M

Sector Composition

Rank Sector Weight
1 Healthcare 19.88%
2 Consumer Discretionary 14.86%
3 Financials 14.2%
4 Technology 12.51%
5 Industrials 9.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OXM icon
2126
Oxford Industries
OXM
$542M
$320K ﹤0.01%
5,660
UHT
2127
Universal Health Realty Income Trust
UHT
$573M
$319K ﹤0.01%
5,580
NXST icon
2128
Nexstar Media Group
NXST
$5.81B
$318K ﹤0.01%
6,680
HAFC icon
2129
Hanmi Financial
HAFC
$963M
$317K ﹤0.01%
13,510
+750
+6% +$17.2K
GMED icon
2130
Globus Medical
GMED
$11.5B
$316K ﹤0.01%
13,280
ITRI icon
2131
Itron
ITRI
$4.5B
$315K ﹤0.01%
7,300
SRGA
2132
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$315K ﹤0.01%
2,923
AGM icon
2133
Federal Agricultural Mortgage
AGM
$2.51B
$314K ﹤0.01%
9,030
KLIC icon
2134
Kulicke & Soffa
KLIC
$5.01B
$314K ﹤0.01%
25,800
SBRA icon
2135
Sabra Healthcare REIT
SBRA
$5.15B
$314K ﹤0.01%
15,233
WPP icon
2136
WPP
WPP
$5.82B
$314K ﹤0.01%
3,000
FBIZ icon
2137
First Business Financial Services
FBIZ
$601M
$313K ﹤0.01%
13,320
+2,800
+27% +$67.7K
PETS icon
2138
PetMed Express
PETS
$43.4M
$313K ﹤0.01%
16,662
-38
-0.2% -$698
AGRX
2139
DELISTED
Agile Therapeutics
AGRX
$313K ﹤0.01%
+21
New +$288K
IVC
2140
DELISTED
Invacare Corporation
IVC
$313K ﹤0.01%
25,800
-9,800
-28% -$116K
LAYN
2141
DELISTED
Layne Christensen Co
LAYN
$312K ﹤0.01%
38,500
+15,500
+67% +$126K
DYN
2142
DELISTED
Dynegy, Inc.
DYN
$312K ﹤0.01%
18,108
-312,130
-95% -$5.42M
BKS
2143
DELISTED
Barnes & Noble
BKS
$310K ﹤0.01%
27,284
+5,400
+25% +$62.5K
KBAL
2144
DELISTED
Kimball International
KBAL
$308K ﹤0.01%
27,090
+11,000
+68% +$125K
GFF icon
2145
Griffon
GFF
$4.8B
$307K ﹤0.01%
18,200
VIA
2146
DELISTED
Via Renewables, Inc. Class A Common Stock
VIA
$307K ﹤0.01%
+3,720
New +$262K
AEPI
2147
DELISTED
AEP Industries Inc
AEPI
$307K ﹤0.01%
+3,810
New +$254K
ASTE icon
2148
Astec Industries
ASTE
$975M
$306K ﹤0.01%
5,450
CNOB icon
2149
Center Bancorp
CNOB
$1.81B
$306K ﹤0.01%
19,483
RGLS
2150
DELISTED
Regulus Therapeutics
RGLS
$305K ﹤0.01%
880
-14
-2% -$10K

Similar funds

T. Rowe Price Associates's Q2 2016 Portfolio in Review

As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.

  • T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
  • T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
  • T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
  • T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
  • T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
  • T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
  • T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.

Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.